International Research Journal of Basic and Clinical Studies

Abstract

Nanomaterials have wide-ranging biomedical applications in prevention, treatment and control of diseases. Nanoparticle based vaccines have proven prodigious prophylaxis of various infectious and non-infectious diseases of human and animal concern. Nano-vaccines outnumber the conventional vaccines by virtue of plasticity in physio-chemical properties and ease of administration. The efficacy of nano-based vaccines may be attributed to the improved antigen stability, minimum immuno-toxicity, sustained release, enhanced immunogenicity and the flexibility of physical features of nanoparticles. Based on these, the nano-based vaccines have potential to evoke both cellular and humoral immune responses. Targeted and highly specific immunological pathways required for solid and long lasting immunity may be achieved with specially engineered nano-vaccines. This review presents an insight into the prevention of infectious diseases and non-infectious diseases using nano-vaccinology.

Keywords

Immunity, Nanoparticles, Vaccine, Pathogens, Prevention

INTRODUCTION

The effective application of nano-vaccines from laboratory to clinical settings has also been identified as an area for future research (Sayed YF 2014). The "chemistry" of nanoparticles and the diverse uses for them is pretty fascinating. Numerous areas of biomedical science, such as therapeutics, such as drug screening and targeted delivery, diagnostics, vaccine production, surgical intervention, gene delivery, prognostics, biomarker assisted mapping, and toxicity of pathogenic organisms, among others, have successfully used nanoparticles (Aljabali AA et al., 2020). Inorganic and synthetic polymeric nanomaterials, such as liposomes, proteasomes, emulsions, nano-beads, ISCOMs, and biological polymeric nanoparticles, have been used as nano-carriers and adjuvants to treat both infectious and non-infectious disorders (Oun AA 2020). Nanoparticles are a promising candidate for commercial vaccinations due to the inertia of surface modification and ability to successfully codeliver the adjuvants (Yaqoob AA et al., 2020) Vaccine nano adjuvants also shield the target antigen from disintegration and improved absorption of biological systems by immune mediators (Ni Q et al., 2020). This strategy is flexible because it can repeatedly deliver the antigen, producing immunogenic qualities that are stable (Renu S et al., 2020).

DISCUSSION

Numerous experiments using nano-vaccines have been conducted as preventative measures against serious illnesses like (Collins KA et al., 2017).The schematic representation of nano-vaccinology in a nutshell illustrates the idea of using Nano vaccines from a wider perspective (Xiang SD et al., 2018). A new path towards precision medicine has been made possible by the wide range of nanoparticles used as vaccine scaffolds, enzymes, and cargo (Ding P et al., 2019). These vaccinations could be duplicated in multi-drug resistant pathogen disease models, which historically have provided a huge clinical opportunity (Zhu G et al., 2017). The improved antigen storage, less immunotoxicity, sustained release, increased immunogenicity, and flexibility of physical properties of nano-assembled vaccines may be responsible for their effectiveness. Nano-vaccines offer a great deal of potential and are relatively simple to create. Utilizing the potential of nano-vaccines also makes it possible to create custom, individualised immune therapies. Understanding the precise bio-distribution processes and potential commercialization of nano-vaccines are challenging issues that need to be thoroughly researched and assigned. Clinical trials are necessary for effective commercialization due to the quantification of host immune interactions after exposure to vaccines based on nanotechnology. The unique manuscript takes into account the cutting-edge applications, prospects, and promises of nano-vaccines for treating human and animal diseases. For the purpose of commercialising nano-vaccines in clinical settings, several quick insights and recommendations have been made. A summary of the research innovation as a whole. Antigen distribution similar to how using biopolymers could improve endocytosis by host cells due to ionic cross-linkages, this internalisation induces a regular pattern of exposure to cells that present antigens, producing a consistent immune response. The interaction and front-line reaction of numerous host immunomodulatory define this response. Due to hydrophobic interactions, the liposomal vaccine carriers can promote fusion within cellular membranes. Further enhancing cytosolic release, which is particularly desirable in DNA-based vaccines, is the cationic nature as well. b Most notably, vaccinations based on nanoparticles have been demonstrated to promote a longer host immunological memory. This characteristic, along with the capacity to induce antigen-specific mucosal immunity, is the foundation of the widespread acceptance of nanovaccines.

CONCLUSION

Brief route chosen by nano-vaccines to advance the host's humoral and/or cell-mediated immunity are being demonstrated. Due to proteolytic degradation inside the cells, the nucleic peptides may become extremely unstable inside the host cells and may fail to produce the intended immunological response. Nano-adjuvants offer biologically suitable carrier platforms that improve host immune stimulation for a stable and reliable immunity as well as antigen protection and sustained release. Use of natural biomolecules as nano-carriers for vaccines have shown extended span, more stable and widespread peripheral tissue response in cancer immune therapy. These biomolecules include albumin, chitosan, mannose, peptides, enzymes, chemical immunomodulatory, or immunoglobulins. Nanovaccines have revolutionised the field of by avoiding cellular degradation pathways and achieving efficient absorption up to blood arteries, tiny science. There are more than 10 commercial vaccines being used in clinical trials or human use as a result of their excellent performance in pre-clinical and clinical trials for nano-vaccines based on liposomes and VLPs. The swine circovirus vaccine, human cervical cancer and anti-hepatitis B Nano vaccines, and multiepitope anti-malarial and anti-hepatitis B vaccinations are examples of traditional VLP-based commercial vaccines. A very special and highly precise feature of nano-vaccines is the appropriate level of epitope density and co-stimulation. Future designed vaccines have a great deal of potential if nanomaterials can be improved to selectively promote one of the desired, antigen-specific immune responses in order to attain optimal immunity.

REFERENCES

1. Sayed YF, El Banna HA, Elzorba HY, Galal AM (2019). Application of some nanoparticles in the field of veterinary medicine. Int J Vet Sci Med. 7: 78-93.

Indexed at, Google Scholar, Crossref

2. Aljabali AA, Bakshi HA, Hakkim FL, Haggag Y, Al Batanyeh MK, et al (2020). Tambuwala Albumin Nano-Encapsulation of Piceatannol Enhances Its Anticancer Potential in Colon Cancer Via Downregulation of Nuclear p65 and HIF-1α Cancers 12.

Indexed at, Google Scholar, Crossref

3. Oun AA, Shankar S, Rhim JW (2020). Multifunctional nanocellulose metal and metal oxide nanoparticle hybrid nanomaterials. Crit Rev Food Sci Nutr. 60: 435-460.

Indexed at, Google Scholar, Crossref

4. Yaqoob AA, Ahmad H, Parveen T, Ahmad A, Oves M, et al (2020). Recent advances in metal decorated nanomaterials and their various biological applications: a review. Front Chem. 8.

Indexed at, Google Scholar, Crossref

5. Ni Q, Zhang F, Liu Y, Wang Z, Yu G, et al (2020). A bi-adjuvant nano vaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer. Sci Adv. 6.

Indexed at, Google Scholar, Crossref

6. Renu S, Markazi AD, Dhakal S, Lakshmanappa YS, Shanmugasundaram R, et al (2020).Oral deliverable mucoadhesive chitosan-salmonella subunit nanovaccine for layer chickens. Int J Nanomed Nanosurg. 15: 761-777.

Indexed at, Google Scholar, Crossref

7. Collins KA, Snaith R, Cottingham MG, Gilbert SC, Hill AVS, et al (2017). Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine. Sci Rep. 7

Indexed at, Google Scholar, Crossref

8. Xiang SD, Wilson KL, Goubier A, Heyerick A, Plebanski M, et al (2018) Design of peptide-based nanovaccines targeting leading antigens from gynecological cancers to induce HLA-A2.1 restricted CD8+ t cell responses. Front Immunol. 9.

Indexed at, Google Scholar, Crossref

9. Ding P, Jin Q, Chen X, Yang S, Guo J, et al (2019). Nanovaccine confers dual protection against influenza A virus and porcine circovirus type 2. Int J Nanomed Nanosurg. 14: 7533-7548.

Indexed at, Google Scholar, Crossref

10. Zhu G, Lynn GM, Jacobson O, Chen K, Liu Y, et al (2017) Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy. Nat Commun. 8.

Indexed at, Google Scholar, Crossref